ImmuneBridge
San Francisco, US · Founded 2022 · Delaware corporation · 9 known investors
Find your way into ImmuneBridge
11,828 people in our graph share verified history with the ImmuneBridge team — schools, employers, funds. One of them is your warm intro.
Hemant Tanejaunlockedknows Peretz Partensky · together at Y Combinator
×5knows the team · via University of Cambridge
×6knows the team · via Y Combinator
ImmuneBridge is a company working in cell-based cancer immunotherapy, including research on engineered natural killer cells for solid tumor treatment.
Founders & leadership
ImmuneBridge was founded in 2022 by Peretz Partensky.
PP
Peretz PartenskyinFounder · AdvisorPeretz Partensky holds a PhD in biochemistry and epigenetics from UCSF, with research focused on chromatin biology and cell identity. He previously served as VP of Product & Data at an Optum/Anthem-backed healthcare company and has co-founded multiple companies that collectively raised over $100 million.
SA
Stuart Alexander JacobsonExecutive
NH
Nina HorowitzinChief Executive Officer
RT
Rui TostoesinChief Technology Officer
AJ
Alicia JacksonNamed on SEC filing
Board
DM
Dylan MorrisBoard director
NI
Nadiya IshnazarovaBoard director
OA
CZ
GA
Gregory A. BonfiglioBoard director
TF
Thomas FarrellBoard director
MK
Mary Kim WarrenBoard director
Investors · 9
M VenturesLos Angeles · $10.8M
NFXSan Francisco · $250K – $5Mvia Omri Amirav Drory · board
__Twitter.png)
Gaingelsreported · 2 sourcesNew York · $200K – $500K
Healthspan Capitalreported · 2 sourcesOxford · $5K
Insight Partnersreported · 2 sourcesNew York · $120M – $350M
One Way Venturesreported · 2 sourcesNew York · $500K – $1.5M
Sand Hill Angelsreported · 2 sourcesMenlo Park · $50K – $2M
Also in the syndicate · 2
LongGame VenturesT.Rx Capital
Funding
SEC filings, press & company announcements$23.5M disclosed across 3 of 4 rounds · 2022–2026
- $7.7Msecond seed roundMar 2026 · 2 sources
NFX (lead), Healthspan Capital, Insight Partners, LongGame Ventures, M Ventures, One Way Ventures, Sand Hill Angels, T.Rx Capital
Source ↗
▶$5.6MraisedApr 2025 · 6 investors · BiotechnologyRule 506(b)
▶$5.6MraisedApr 2025 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dylan MorrisDirector
- Nadiya IshnazarovaDirector
- Omri Amirav-DroryDirector
- Alicia JacksonDirector
- Stuart Alexander JacobsonExecutive Officer, Director
- Thomas FarrellDirector
- Offering amount
- $7.1M
- Amount sold
- $5.6M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$10.2MraisedJan 2023 · 15 investors · BiotechnologyRule 506(b)
▶$10.2MraisedJan 2023 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alicia JacksonDirector
- Cheryl ZimberlinDirector
- Gregory A. BonfiglioDirector
- Peretz PartenskyExecutive Officer, Director
- Dylan MorrisDirector
- Mary Kim WarrenDirector
- Offering amount
- $14.2M
- Amount sold
- $10.2M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through ImmuneBridge went on to found or lead other companies.
Competitors · 7
by search overlapImmune-Onc Therapeutics21 shared keywordsImmune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
Immuneering21 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Inmune Bio18 shared keywordsINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
Inimmune17 shared keywordsInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
Infinimmune16 shared keywordsInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
Bridgebio16 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Immunai16 shared keywordsImmunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.
Companies competing with ImmuneBridge for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does ImmuneBridge do?
- ImmuneBridge is a company working in cell-based cancer immunotherapy, including research on engineered natural killer cells for solid tumor treatment.
- Who founded ImmuneBridge?
- ImmuneBridge was founded by Peretz Partensky in 2022.
- Who are ImmuneBridge's investors?
- ImmuneBridge's investors include M Ventures, NFX, Gaingels, Healthspan Capital, Insight Partners, One Way Ventures, Sand Hill Angels.
- How much funding has ImmuneBridge raised?
- ImmuneBridge has disclosed $23.5M raised across 3 of its 4 known rounds.
- Where is ImmuneBridge headquartered?
- ImmuneBridge is headquartered in San Francisco, US.